Skip to main content
Year archive

Ascletis Pharma Inc. — 2026 filings

All 22 regulatory filings released by Ascletis Pharma Inc. (1672) in 2026, sourced directly from the official regulator.

22 Filings
2026 Period
2026 filings (22)
Filing Released Lang
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2026
Regulatory Filings
2026-05-07 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS TO PRESENT DATA ON MULTIPLE PROGRAMS AT THE 33RD EUROPEAN CONGRESS ON OBESITY (ECO 2026)
Regulatory Filings
2026-05-06 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS TO PRESENT DATA ON MULTIPLE PROGRAMS AT THE AMERICAN DIABETES ASSOCIATION'S 2026 SCIENTIFIC SESSIONS
Regulatory Filings
2026-04-30 English
Annual Report 2025
Regulatory Filings
2026-04-29 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS COMPLETES ENROLLMENT IN U.S. PHASE II STUDY OF ASC30, AN ORAL SMALL MOLECULE GLP-1R AGONIST, FOR THE TREATMENT OF DIABETES
Regulatory Filings
2026-04-27 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2026
Regulatory Filings
2026-04-08 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES FIXED-DOSE COMBINATION OF ASC30, ONCE-DAILY ORAL SMALL MOLECULE GLP-1R AGONIST, AND ASC39, ONCE-DAILY ORAL SMALL MOLECULE AMYLIN-SELECTIVE AMYLIN RECEPTOR
Regulatory Filings
2026-04-07 English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025 AND CHANGE IN THE USE OF PROCEEDS
Earnings Release FY 2025
2026-03-31 English
NOTICE OF BOARD MEETING
Report Publication Announcement
2026-03-18 English
VOLUNTARY ANNOUNCEMENT - ORAL SMALL MOLECULE AMYLIN RECEPTOR AGONIST ASC39 DEMONSTRATED ELORALINTIDE-LIKE AMYLIN SELECTIVITY AND EFFICACY IN PRECLINICAL MODELS
Regulatory Filings
2026-03-17 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES POSITIVE TOPLINE RESULTS FROM U.S. PHASE II, 24-WEEK STUDY FOR ITS ULTRA-LONG-ACTING SUBCUTANEOUS DEPOT FORMULATIONS OF SMALL MOLECULE GLP-1R AGONIST ASC30
Regulatory Filings
2026-03-10 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2026
Regulatory Filings
2026-03-03 English
Next Day Disclosure Return
Share Issue/Capital Change
2026-02-10 English
COMPLETION OF PLACING OF NEW SHARES UNDER THE GENERAL MANDATE
Share Issue/Capital Change
2026-02-10 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2026
Share Issue/Capital Change
2026-02-03 English
PLACING OF NEW SHARES UNDER THE GENERAL MANDATE
Capital/Financing Update
2026-02-03 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES POSITIVE TOPLINE RESULTS FROM ITS PHASE III OPEN-LABEL STUDY OF DENIFANSTAT (ASC40), A FIRST-IN-CLASS, ONCE-DAILY ORAL FASN INHIBITOR FOR ACNE
Regulatory Filings
2026-01-29 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES FIRST PARTICIPANTS DOSED IN A 13-WEEK U.S. PHASE II STUDY WITH ASC30, AN ORAL SMALL MOLECULE GLP-1R AGONIST FOR THE TREATMENT OF DIABETES
Regulatory Filings
2026-01-26 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS SELECTS A NEXT-GENERATION ONCE-MONTHLY SUBCUTANEOUSLY ADMINISTERED GLP-1R/GIPR/GCGR TRIPLE PEPTIDE AGONIST, ASC37, FOR CLINICAL DEVELOPMENT
Regulatory Filings
2026-01-20 English
Monthly Return of Equity Issuer on movements in Securities for the month ended 31 December 2025
Regulatory Filings
2026-01-05 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2025
Share Issue/Capital Change
2026-01-05 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES U.S. FDA IND CLEARANCE FOR 13-WEEK PHASE II STUDY OF ITS ORAL SMALL MOLECULE GLP-1, ASC30, IN PARTICIPANTS WITH DIABETES
Regulatory Filings
2026-01-05 English